GeoVax Labs (GOVX) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology focused on vaccines and immunotherapies for infectious diseases and solid tumors, using proprietary vector platforms.

• GEO-MVA is the near-term priority: an MVA vaccine candidate for mpox, smallpox and other poxviruses, with a pivotal Phase 3 trial planned for Q4 2026; Gedeptin completed Phase 1/2, with combination Phase 2 planned for H2 2027.

• Strategy centers on clinical advancement, regulatory approval and commercialization through internal development plus selective licensing and partnerships; May 2026 reprioritization focused resources on GEO-MVA and Gedeptin and ended active COVID-19 vaccine development.

• Development relies on third-party manufacturers; cGMP GEO-MVA material is ready for late-stage trials, while continuous avian cell-line manufacturing is under development for potential scale-up.

Financial performance and metrics

• FY2025 government-contract revenue $2.489 million vs $3.955 million in FY2024; net loss $21.465 million vs $24.992 million.

• H1 2026 revenue $0 vs $2.489 million H1 2025; net loss $9.688 million vs $10.727 million.

• H1 2026 R&D expense $7.014 million vs $10.084 million H1 2025; FY2025 R&D expense $18.122 million vs $23.714 million FY2024.

• Cash and equivalents were $3.143 million and stockholders’ equity $1.761 million at June 30, 2026; auditor reported substantial doubt about going-concern ability.

• Existing cash plus potential, discretionary revolving-loan draws was projected to fund operations into December 2026; offering proceeds plus cash were projected to extend runway into Q1 2027.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.628 million, assuming all 29,585,798 securities are shares at $0.169, no pre-funded warrants and no overallotment exercise.

• Planned uses include GEO-MVA’s Phase 3 trial, R&D, manufacturing, clinical studies, capital expenditures, working capital and general corporate purposes.

• Up to $2.5 million may fund marketing and advertising services for financial-community communications; no such service agreements had been entered into as of the prospectus date.

• No proceeds are intended for repayment of the revolving loan; management retains broad discretion over allocation.